Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03033238
Other study ID # U01AG019069
Secondary ID U01AG019069
Status Completed
Phase
First received
Last updated
Start date January 2003
Est. completion date December 2020

Study information

Verified date February 2021
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to investigate opportunities for prevention and treatment of knee osteoarthritis (OA) by evaluating potentially modifiable risk factors for disease and poor pain and physical function outcomes especially among those with early or mild knee symptoms. The goal of the study is to find novel strategies to prevent disease at an early stage and to limit the impact of disease once it has occurred.


Description:

MOST study participants in the "Existing Cohort" (3,026 subjects) were enrolled in the original study in 2003-2005. Surviving Existing Cohort participants without end-stage knee osteoarthritis will be asked to participate in the 144-, 152-, 160- and 168-month follow-up contacts. In addition, in 2016-2018 the cohort will be enriched by the recruitment of an additional 1,500 "New Cohort" participants with early or mild knee symptoms. The goal of the study is to find novel strategies to prevent disease at an early stage.


Recruitment information / eligibility

Status Completed
Enrollment 4185
Est. completion date December 2020
Est. primary completion date December 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years to 79 Years
Eligibility Inclusion Criteria for "New Cohort" Participants: - Age 45 to 69 Years (Adult, Senior) - Males and Females - Healthy Volunteers - Community-based Sample Exclusion Criteria for "New Cohort" Participants: - Rheumatoid or inflammatory arthritis (based on self-report and use of medications specific to these conditions) - Serious health condition e.g., end-stage renal disease, etc. that would likely limit follow-up to less than 2-3 years - Plan to relocate out of geographic region in next 3 years - Not able to walk without the aid of a person or assistive device - Knee joint replacement surgery in either knee - Neither knee fits in the MRI knee coil (determined during Screening Visit). - Not competent to give informed consent - Advanced structural tibiofemoral or patellofemoral knee OA disease (KL grade 3 or 4) in either knee (Determined by Knee X-ray Screening)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama
United States Boston University School of Medicine Boston Massachusetts
United States University of Iowa Iowa City Iowa

Sponsors (5)

Lead Sponsor Collaborator
University of California, San Francisco Boston University, National Institute on Aging (NIA), University of Alabama at Birmingham, University of Iowa

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Worsening knee pain Worsening knee pain defined as reaching minimally clinically important difference (MCID) for worsening on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain questionnaire Change from baseline (144-month) at =2 follow-up contacts (152-, 160-, 168-month follow-up contacts)
Primary Incident cartilage loss on MRI Incidence of cartilage loss on MRI extending to the bone Change from baseline (144-month) at 168-month follow-up contact
Primary Function loss Defined as minimally clinically important difference (MCID) for worsening on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function questionnaire Change from baseline (144-month) at =2 follow-up contacts (152-, 160-, 168-month follow-up contacts)
Secondary Onset of constant knee pain Self- report Change from baseline (144-month) at =2 follow-up contacts (152-, 160-, 168-month follow-up contacts)
Secondary Worsening on MRI Worsening cartilage scores, bone marrow lesion, or meniscal damage Change from baseline (144-month) at 168-month follow-up contact
Secondary Worsening on X-ray Increased Kellgren-Lawrence (KL) grade score, new KL grade 2 score, or semi-quantitative joint space loss in any compartment Change from baseline (144-month) at 168-month follow-up contact
Secondary New onset knee buckling Self-report Change from baseline (144-month) at =1 follow-up contact (152-, 160-, 168-month follow-up contacts)
Secondary New repeated falls Self-report Change from baseline (144-month) at =1 follow-up contact (152-, 160-, 168-month follow-up contacts)
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02784041 - Single Adductor-canal-block Versus Peri-articular Infiltration on Outcome After Total Knee Arthroplasty N/A
Completed NCT02966613 - Fully Disposable Patient-Specific Instrumentation N/A
Recruiting NCT03074994 - The Comparative Efficacy of Peri-articular and Intraarticular Tranexamic Acid in Total Knee Arthroplasty Phase 2
Completed NCT00137410 - Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee Phase 3
Recruiting NCT03360500 - Cryotherapy Associated With Exercise in Pain Control and Physical Function in Individuals With Knee Osteoarthritis N/A
Completed NCT02967874 - Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment Phase 1/Phase 2
Completed NCT01899417 - Costs and Benefits of ConforMIS iTotal® Knee Replacement System Versus Standard Total Knee
Completed NCT02967744 - NSAID Treatment of Patients With Osteoarthritis N/A
Completed NCT01042093 - Efficacy of Multimodal Perioperative Analgesia With Periarticular Drug Injection in Total Knee Arthroplasty(TKA) N/A
Completed NCT03011112 - Can 3D Kinematic Parameters Assess the Symptomatic and Functional Severity of KOA? N/A
Completed NCT02975154 - Microcurrent Therapy in the Treatment of Osteoarthritis of the Knee N/A
Completed NCT03684850 - Knee Brace and Biomechanical Footwear in the Treatment of Knee Osteoarthritis. N/A
Completed NCT03007576 - Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem) Phase 1